← All organizations

InterMune

For profitContributed to NME

Also known as: Intermune | InterMune Deutschland GmbH

Phase 1 Phase 2 Phase 3 Phase 4

Highest phase reached

Phase 4

First clinical trial

First marketed drug

First NDA

Last known activity

Jun 1, 2011

Acquired by Roche on Jan 1, 2014

Timeline

1990s

Jul 1, 1998
InterMune— Founded

2000s

Jan 1, 2007
Marnac, Inc.— Acquired

2010s

Jan 1, 2014
Roche— Acquired By
Oct 15, 2014
pirfenidone— NDA Organization
Oct 15, 2014
pirfenidone— NDA Secondary Org

Drugs by trial phase (19 distinct, 22 trials)

Phase 4 (3 own, 0 via acquisition)

Phase 3 (3 own, 0 via acquisition)

Phase 2 (13 own, 0 via acquisition)

Marketed drugs (1)

pirfenidone

Subsidiaries (1 direct, 1 total across the full acquisition tree)

Marnac, Inc.

Recent trials (32)

NCT01366209Study chairPhase 3Jun 1, 2011
NCT00753467CollaboratorPhase 2Sep 1, 2008
NCT00786643CollaboratorPhase 2Feb 1, 2006
NCT00266318CollaboratorPhase 4Dec 1, 2005
NCT00207402CollaboratorPhase 4Oct 1, 2005
NCT00211692CollaboratorPhase 3Jul 1, 2005
NCT00148863CollaboratorPhase 2Jun 1, 2004
NCT00084279Study directorPhase 2Apr 1, 2004
NCT00084279Lead sponsorPhase 2Apr 1, 2004
NCT00075998Lead sponsorPhase 3Dec 1, 2003
NCT00076635Lead sponsorPhase 3Nov 1, 2003
NCT00057447Study directorPhase 1/Phase 2Mar 1, 2003
NCT00057447Lead sponsorPhase 1/Phase 2Mar 1, 2003
NCT00501644CollaboratorPhase 2Jan 1, 2003
NCT00052052Study directorPhase 2Sep 1, 2002

Details

Founded: Brisbane, CA, US Jul 1, 1998
First NDA: Oct 15, 2014
Last known activity: Jun 1, 2011

Designations held

Orphan drug
Fast track
Priority review
Breakthrough therapy

Notes

Acquired by Roche - 2014